Skip to main content
Top

14-08-2024 | Alzheimer's Disease | Panel Discussion | Article | Lilly

Experts in Conversation

Real-world experience with amyloid-targeting treatments and preparedness for fluid biomarkers in practice

Gemma Salvadó, Sharon A Brangman, and Argonde van Harten explore what the latest developments from AAIC 2024 mean for clinical practice. How can blood-based biomarkers best be applied? What should you consider when selecting patients for amyloid-targeting therapies?

Related topics

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more